Pharmacoeconomic analysis of the neuroprotective medicines in the treatment of ischemic stroke
Ягудина Р. И., Куликов А. Ю., Крyлов В. А., Соловиева Е. Y., Федин А. И.
Журнал неврологии и психиатрии им. C.C. Корсакова
Т. 119, Вып. 7, С. 60-68
Опубликовано: 2019
Тип ресурса: Статья
DOI:10.17116/jnevro201911907160
Аннотация:
Objective. To perform a pharmacoeconomic analysis of the most frequently prescribed neuroprotective medicines for treating patients with mild ischemic stroke in the acute and early rehabilitation periods in the Russian Federation. Material and methods. Three medical technologies were compared: ethylmethylhydroxypyridine succinate (mexidol), inosine + nicotinamide + riboflavin + succinic acid (cytoflavin) and a deproteinized hemoderivate of the blood of calves (actovegin). Cost minimization analysis, budget impact analysis and sensitivity analysis were performed based on the indirect comparison results. Results. Efficacy analysis shows that mentioned above medicines have the same efficacy: mean difference mexidol is 0,2 (CI min 0,25; max 0,65), cytoflavin - 0,61 (CI min 0,23; max 0,99), actovegin 0,2 (CI min 0,18; max 0,22). The cost minimization analysis for the Russian Federation shows that mexidol therapy is associated with the lowest costs, while savings are observed both in the eva
Ключевые слова:
Budget impact analysis; Cost minimization analysis; Indirect comparison; Ischemic stroke; Neuroprotectors; Pharmacoeconomics
actovegin; cytoflavin; emoxipin; inosine; mexidol; neuroprotective agent; nicotinamide; riboflavin; succinic acid; neuroprotective agent; Article; brain ischemia; budget; cost effectiveness analysis; cost minimization analysis; drug cost; human; neurorehabilitation; pharmacoeconomics; sensitivity analysis; tablet formulation; animal; bovine; brain ischemia; cerebrovascular accident; economics; Russian Federation; Animals; Brain Ischemia; Cattle; Economics, Pharmaceutical; Humans; Neuroprotective Agents; Russia; Stroke
Язык текста: Русский
ISSN: 2309-4729
Ягудина Р. И. Роза Исмаиловна 1965-
Куликов А. Ю. Андрей Юрьевич 1972-
Крyлов В. А.
Соловиева Е. Y.
Федин А. И.
Yagudina R. I. Roza Ismailovna 1965-
Kulikov A. Yu. Andrej Yuryevich 1972-
Krylov V. A.
Solovieva E. Y.
Fedin A. I.
Pharmacoeconomic analysis of the neuroprotective medicines in the treatment of ischemic stroke
Текст визуальный непосредственный
Журнал неврологии и психиатрии им. C.C. Корсакова
Издательство Медиа Сфера
Т. 119, Вып. 7 С. 60-68
2019
Статья
Budget impact analysis Cost minimization analysis Indirect comparison Ischemic stroke Neuroprotectors Pharmacoeconomics
actovegin cytoflavin emoxipin inosine mexidol neuroprotective agent nicotinamide riboflavin succinic acid neuroprotective agent Article brain ischemia budget cost effectiveness analysis cost minimization analysis drug cost human neurorehabilitation pharmacoeconomics sensitivity analysis tablet formulation animal bovine brain ischemia cerebrovascular accident economics Russian Federation Animals Brain Ischemia Cattle Economics, Pharmaceutical Humans Neuroprotective Agents Russia Stroke
Objective. To perform a pharmacoeconomic analysis of the most frequently prescribed neuroprotective medicines for treating patients with mild ischemic stroke in the acute and early rehabilitation periods in the Russian Federation. Material and methods. Three medical technologies were compared: ethylmethylhydroxypyridine succinate (mexidol), inosine + nicotinamide + riboflavin + succinic acid (cytoflavin) and a deproteinized hemoderivate of the blood of calves (actovegin). Cost minimization analysis, budget impact analysis and sensitivity analysis were performed based on the indirect comparison results. Results. Efficacy analysis shows that mentioned above medicines have the same efficacy: mean difference mexidol is 0,2 (CI min 0,25; max 0,65), cytoflavin - 0,61 (CI min 0,23; max 0,99), actovegin 0,2 (CI min 0,18; max 0,22). The cost minimization analysis for the Russian Federation shows that mexidol therapy is associated with the lowest costs, while savings are observed both in the eva